CD22 and acute lymphoblastic leukemia: Results from a Children’s Oncology Group trial using anti-CD20 mAb rituximab and anti-CD22 mAb epratuzumab alone or in conjunction with chemotherapy in relapsed B-ALL indicate that therapeutic mAbs can be safely administered in children [4].